To investigate which parts of the acetylcholine receptor are involved in the initiation and development of myasthenia gravis (MG), peptides representing different sequences of the human acetylcholine receptor a-subunit were synthesized. These peptides were tested for their ability to stimulate T cells of myasthenic patients and healthy control patients in proliferation assays and to bind to sera antibodies. Three of eight peptides discriminated significantly between the two groups in the proliferation assay, as well as in their ability to bind to serum antibodies. HLA-DR3 and DR5 were associated with proliferative responses to specific AChR peptides in the group of myasthenics. Acetylcholine receptor epitopes that might play a specific role in myasthenia gravis thus were demonstrated.
Introduction
Myasthenia gravis (MG)' is a very well-characterized autoimmune disorder (1) . The symptoms of MG are caused by an antibody-mediated autoimmune response to the nicotinic acetylcholine receptor (AChR) . However, what initiates and regulates the autoimmune reactivity in MG is still unclear and there is no definitive cure for this disease (1) . The higher frequency of certain histocompatibility antigens (HLA-B8, DR3) (2) suggests that the MHC might be involved in regulation of susceptibility to MG. Further, only limited information is available on the T and B cell response to specific epitopes of AChR.
To explain the role of regulatory T cells in the pathogenesis of MG, it is important to study MG patients for their T cell immune responses to the relevant antigen, namely human AChR. However, because of minute amounts of AChR in 1. Abbreviations used in this paper: AChR, acetycholine receptor; MG, myasthenia gravis.
human tissue and complicated purification methodologies, it is not possible to obtain AChR in sufficient quantities to enable screening a large number of myasthenic patients. Therefore, very few studies have been performed to measure T cell reactivity of MG patients to the human AChR (3, 4) . It appears that the use of synthetic peptides from various regions in the human AChR molecule should alleviate the above problem. Further, this approach will allow for the characterization of a determinant(s) in the human AChR that is recognized by T cells of MG patients. As T cell epitopes are recognized in conjunction with class II major histocompatibility products, it might be possible to correlate certain AChR determinants with specific HLA-D products.
In this study, PBL of patients with MG and of healthy control patients were tested for their capacity to proliferate when stimulated in vitro with synthetic peptides that represent different sequences of the human AChR a-subunit. All patients were typed for their HLA class I and class II antigens to find out a possible correlation between the proliferative responses and a specific HLA gene(s). Antibody reactivity to the different sequences of the human AChR was also determined in the sera of the patients.
Methods
MG patients and healthy control patients. 45 patients with MG, (17 males, 28 females) examined at the Department of Neurology, Hadassah Medical Center, Jerusalem, participated in this study after giving informed consent. The patients' age ranged from 18 to 76 yr and duration ofdisease ranged from I to 30 yr. The diagnosis was based on clinical manifestations of fluctuating skeletal muscle weakness and fatigability. Serum antibody to AChR (5) was found in 40 patients (89%). In the five patients without antibody, the diagnosis was confirmed by electrodiagnostic (decremental muscle potential response with a low-frequency stimulation) and pharmacologic (positive testing with edrophonium) criteria. 14 patients underwent thymectomy; thymoma was found in 4. 34 patients were treated with prednisone and/or azathioprine. A control group of 33 healthy donors matched with the patients in sex, age, and ethnic origin was tested simultaneously.
Antigens. Seven peptides representing different regions of the human AChR a-subunit and one peptide with a sequence of the Torpedo AChR a-subunit were synthesized in our own laboratories. The sequences of the different peptides are shown in Table I . Peptide synthesis and characterization were carried out as previously described (6, 7) .
RIA. Antibody levels specific to the different peptides in the sera of patients and healthy control individuals were determined by solid phase RIA (8) . Plates were coated with 100 ul of 50 Ag/ml AChR peptides in PBS containing 0.2% glutaraldehyde and washed with PBS HLA examination. PBL were isolated from heparinized blood samples of donors as described above. HLA-A,B,C antigens were determined by the microcytotoxity technique (10) . HLA-DR,DQ typing was performed on T cell-depleted, B cell-enriched lymphocytes by extended incubation cytotoxicity testing (11) . Each individual was typed at least twice. Generally, four to six alloantisera were used to test for each specificity. The sera used to determine the HLA-A,B,C, DR and DQ antigens, were of local origin, from other investigators and some were from the Ninth Histocompatibility Workshop "genetic" and "disease" set.
Statistical analyses. Significance ofdifferences between blood samples of patients and controls in proliferative responses and antibody levels was examined using the Chi-square test with Yate's correction or Fisher's exact test. A P value of < 0.05 was considered to be significant. It should be noted that not all patients that were HLA typed had proliferation and/or antibody tests performed; conversely, not all patients that had these tests performed could be HLA typed.
Results
Proliferative responses ofPBL ofMG patients to peptides representing sequences ofthe human AChR. PBL of MG patients and of healthy controls were tested for their ability to proliferate in the presence of an in vitro stimulus with the various peptides representing regions of the AChR a-subunit that are listed in Table I . Representative results of proliferative responses of PBL of one control and three MG patients to one peptide (p195-212) are shown in Fig. 1 . As can be seen, the PBL of the healthy control and of one of the patients did not proliferate in the presence of p195-212, whereas significant proliferative responses were observed with PBL of the other two patients, although they differed in the dose of peptide required for maximum proliferation.
The stimulation indices ofthe proliferative responses ofthe 28 patients and 33 controls tested with p195-2 12 are presented in Fig. 2 . A stimulation index > 3 was considered positive. It is clear from the figure that a significantly larger number of patients responded to p195-212 compared with the healthy controls (P < 0.001). Table II summarizes the results of the proliferative assays specific to eight sequences of the AChR performed with PBL of MG patients and healthy controls. As shown in the table, the myasthenic patients responded better to all the peptides.
However, only three peptides (pl95-212, p257-269, and p310-327) could discriminate significantly between MG patients and controls on the basis ofthe proliferative responses of PBL. Scatter diagrams for responses to p257-269 and p310-327 are shown in Figs. 3 and 4. The differences between MG patients and controls were the most significant when the responses to p195-212 were measured (Table II) .
Antibody levels specific to synthetic peptides representing AChR in sera ofMG patients. It was of interest whether sera of patients with myasthenia gravis possess antibodies that react with the different peptides representing the AChR a-subunit.
Sera of MG patients and of controls were tested by RIA to detect antibody titers specific to seven peptides used in this study. majority (31 of 39) of sera of the MG patients possessed antibodies that reacted with p195-212, whereas sera of only 2 of the 31 healthy controls tested reacted with this peptide (P < 0.001). Thus, p195-212 also discriminated significantly between patients and controls based on sera antibody titers. Table V demonstrates that all seven HLA-DR3 type patients responded to p257-269 (P < 0.0003). The one HLA-DR3 healthy individual also responded to p257-269. Non-HLA-DR3 patients also responded to p257-269, but less frequently (7 of 7 vs. 6 of 16, P < 0.006). Table VI demonstrates that 10 of 12 (83%) of the HLA-DR5 myasthenic patients responded to p195-212 by proliferation compared with 2 of 12 (17%) of myasthenic DR5 carriers who did not respond. In the group of HLA-DR5 healthy controls, the distribution was different, with 3 of 14 (21%) responding and 11 of 14 not responding to p195-212 (P < 0.007). Non- (6, (12) (13) (14) (15) . In this report, seven peptides that represent sequences of the human AChR a-subunit and one peptide with a region of the Torpedo AChR (Table I) (19, 20) . Therefore, it is of interest that peptides p195-212, p257-269, and p310-327 discriminated significantly between MG patients and controls based on sera antibodies that bound to these peptides (Table III and Figs. 5-7). In agreement with the proliferative assays, p195-212 was the most discriminative with 79.5% of the pa-0 a. tients' sera reacting with it, in contrast to 6.5% ofthe sera taken from controls (Fig. 4 , The majority of patients responded to more than one peptide in both the proliferative and antibody assays (Table IV) . These data are important when considering the implications for therapy. Thus, the response to more than a single epitope will need to be suppressed. nants between the AChR a-subunit and membrane proteins of several bacteria have been reported (21) . A higher incidence of HLA-B8, DR3 has been reported for MG patients (2) . Indeed, of the Israeli group of MG patients we tested, 27% were determined to express jointly HLA-B8, DR3, a significantly higher percentage from that observed in the Israeli healthy control group. This observation is of special interest because many autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis in the Israeli population do not follow the reported HLA associations (22) (23) (24) (25) (26) (27) . Class II HLA polymorphisms have been described in MG patients who are HLA-DR 3 (25) . The HLA-DR a and DR # genes and HLA-DQ a and : genes have been sequenced in Caucasoid MG patients. No sequence difference was seen between MG patients and healthy controls (28) . Thus, polymorphism, linked to MG in the HLA-D region may map to HLA-DP or perhaps DX and DZ. In the mouse, responsiveness to AChR is controlled by the I-A : chain (26, 27) .
This study suggests that peptides of AChR are particularly immunogenic for certain HLA-DR types. HLA-DR5 individuals responded better than healthy controls to p195-212. Moreover, all HLA-DR3 respond to p257-269. It has been demonstrated that immunogenic peptides bind directly to class II MHC products (29) . In this context, it is possible that p195-212 binds more readily with an MG-associated class II (31) . Our studies demonstrate significant differences between MG patients and healthy controls in the immune response potential to various sequences of the human AChR and its association with HLA. Other epitopes of AChR, when tested, may also be shown to play a critical role in the pathogenesis of MG.
